The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
250
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Net adverse clinical events (composite of efficacy and safety [bleeding] endpoints)
Time frame: 30-days
all cause mortality, myocardial infarction, or unplanned revascularization for ischemia
Time frame: 30-days
Bleeding Academic Research Consortium grade III or V bleeding events
Time frame: 30-days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.